

EHSF  
goes Hybrid

Facing HS according to the Renaissance style

**EHSF 2023**

**FIRENZE | FEBRUARY 8–10, 2023**

12<sup>th</sup> CONFERENCE OF THE EUROPEAN  
HIDRADENITIS SUPPURATIVA FOUNDATION

## TABLE OF CONTENTS

### 01 | WELCOME MESSAGE

03

### 02 | GENERAL INFORMATION

04

### 03 | ABOUT EHSF

Our history	06
1 <sup>st</sup> International Hidradenitis Suppurativa Research Symposium	06
Last HSF, Inc. Board with European Participation	06
Inauguration of EHSF e.V.	07
Founding Members	07
Congresses	07
Our Goals	07

### 04 | COMMITTEES

Organizing Committee	10
Scientific Committee	11
Local Organizing Committee	12
Awards Committee	13

### 05 | FEBRUARY 08, 2023 PROGRAM WED

Overview	14
Program	15

### 06 | FEBRUARY 09, 2023 PROGRAM THU

Overview	16
Program	17

### 07 | FEBRUARY 10, 2023 PROGRAM FRI

Overview	20
Program	21

### 08 | POSTERS

26

### 09 | IMPRINT

42

## WELCOME MESSAGE

Dear colleagues,

We are very proud to welcome you in Florence for the 12<sup>th</sup> Conference of the European Hidradenitis Suppurativa Foundation. The Conference will be held in a hybrid mode from 8<sup>th</sup> to 10<sup>th</sup> February 2023.

In recent years, there has been growing interest within scientific community about hidradenitis suppurativa (HS), as demonstrated by the outstanding attendance at this event. After years of remote events, EHSF 2023 will be an excellent opportunity to meet again in person around the most exciting scientific works and meet and discuss with experts on specific topics. In this Conference, we have tried to involve as many representatives of different disciplines as possible, in an attempt to make multidisciplinary teamwork the norm rather than the exception. Our target for this Conference is to re-consider the HS patient as part of a human-centered medicine according to the Renaissance style and no city like Florence could have been more suitable for this ambitious purpose.



**Francesca Prignano, MD, PhD**

Associate Professor

Dept. Health Sciences,  
Div. Dermatology - University of Florence Medical School,  
Firenze, Italy

# GENERAL INFORMATION

## WLAN

Name: **Novartis**

Password: **EHSF2023**

## REGISTRATION DESK OPENING HOURS

**Wednesday, February 8, 2023**

08.00 – 18.30

**Thursday, February 9, 2023**

07.30 – 16.30

**Friday, February 10, 2023**

07.30 – 13.00

## WELCOME RECEPTION

**Wednesday, February 8, 2023**

18.00 – 21.00

Exhibition area @ congress venue

At the end of the first meeting day, you are kindly invited to the Welcome Reception – taking place in the exhibition area. It will be an enjoyable opportunity to meet and talk in-person.

## POSTER EXHIBITION – OPENING HOURS

**Wednesday, February 8, 2023**

08.00 – 18.00

**Thursday, February 9, 2023**

07.30 – 16.00

**Friday, February 10, 2023**

07.30 – 17.00

## INDUSTRY – OPENING HOURS

**Wednesday, February 8, 2023**

08.00 – 21.00

**Thursday, February 9, 2023**

08.00 – 16.30

**Friday, February 10, 2023**

08.00 – 18.30

Please visit our industry exhibitors at their booths in the exhibition area as well as the digital hospitality lounges at our conference platform and contact the industry representatives.

## GUIDED TOUR

**Thursday, February 9, 2023**

16:30 meeting point Firenze Fiera

17:00 arrival at Accademia

18:00 start of the city tour

18:45 end of the tour and return to the hotel

## NETWORKING DINNER @PALAZZO BORGHESE

Palazzo Borghese

Via Ghibellina, 110

50122 Firenze

**Thursday, February 9, 2023**

Doors open: 19.30

The Banquet will take place at Palazzo Borghese, a historical palace re-structured in the XV century, located in the city centre of Florence.

Palazzo Borghese is one of the most exemplary buildings of neoclassical architecture in the Tuscan main city, particularly of the historic center of Florence. The ancient building is in fact located just a stone's throw from Piazza del Duomo and Piazza della Signoria.

After a Welcome cocktail, dinner will be served at the "Galleria Monumentale", an architectural and artistic gem of two hundred square meters enriched of paintings, stuccoes, bas-reliefs, niches, statues, columns, and draperies.

Dresscode: smart casual

## MEET THE EXPERTS!

**Friday, February 10, 2023**

Cantinetta Antinori


Piazza degli Antinori, 3

50123 Firenze

Start: 20:00

## CERTIFICATES

The certificates will be sent by mail after the conference.



## ABOUT EHSF

### OUR HISTORY

#### Founding of HSF, Inc.

In 2005, Mrs. Michele Barlow, a patient from San Diego, CA, USA, organized first funding to initiate the Hidradenitis Suppurativa Foundation, Inc. (HSF, Inc.), a tax-deducted organization according to the US law. In addition to Mrs. Barlow as president and co-founder, the first board of HSF Inc., Prof. Dr. Ralf Paus, Luebeck, Germany, director of basic research and co-founder, Prof. Dr. Christos C. Zouboulis, Dessau, Germany, director of clinical research and co-founder, Mrs. Christine E. Pasela, San Diego, CA, USA, Mrs. Sylvia Shawcross, Chelsea, Quebec, Canada, Mrs. Mary Veta, San Diego, CA, USA, and Mrs. Lynn Edward Wedell, San Diego, CA, USA. Experimental Dermatology became the official scientific journal of the HSF, Inc.

#### 1<sup>st</sup> INTERNATIONAL HIDRADENITIS SUPPURATIVA RESEARCH SYMPOSIUM

The 1st International Hidradenitis Suppurativa Research Symposium took place on 30.03–02.04.2006 in Dessau, Germany. The milestones of the Symposium were the so-called Dessauer definition of the disease and the HSF 2006 Outstanding Investigator Award presented to Prof. Gregor B. E. Jemec. The attendees of this legendary meeting were Dr. David R. Adams, USA; Dr. Andreas Altenburg, Germany; Mrs. Michelle Barlow, USA; Dr. Martina Brunner, Germany; Dr. George Cotsarelis, USA; Dr. William Danby, USA;

Dr. Alain Dupuy, France; Dr. Sabine Fimmel, Germany; Dr. Wolfgang Hartschuh, Germany; Dr. Dolores Herreros, Spain; Dr. Dorothee Hochheim, Germany; Dr. Peter Hull, Canada; Dr. Gregor Jemec, Denmark; Dr. Yvonne Kroening, Germany; Dr. Ichiro Kurokawa, Japan; Dr. Hjalmar Kurzen, Germany; Dr. Evgenia Makrantonaki, Germany; Dr. Anirban Mandal, UK; Dr. Lynette Margesson, USA; Dr. Wolfgang, C. Marsch, Germany; Dr. W.H. Irwin McLean, Scotland; Dr. Samuel L. Moschella, USA; Dr. Ralf Paus, Germany; Dr. Uppala Radhakrishna, USA; Dr. Jean Revuz, France; Dr. Jihai Shi, Germany; Dr. Rodney Sinclair, Australia; Dr. John Sundberg, USA; Dr. Gilles Tachon, France; Dr. Antje Thielitz, Germany; Dr. Athanasios Theodoridis, Germany; Dr. Frangiski Tsatsou, Germany; Dr. Jan von der Werth, UK; and Dr. Christos C. Zouboulis, Germany.

#### LAST HSF, INC. BOARD WITH EUROPEAN PARTICIPATION

On 15.02.2012 a new HSF, Inc. board was elected (and re-elected on 11.02.2018) with Prof. Dr. Christos C. Zouboulis, Dessau, Germany, President and responsible for hidradenitis suppurativa/acne inversa guidelines, Prof. Gregor B.E. Jemec, Copenhagen, Denmark, vice president and responsible for clinical research, Prof. Dr. Ralf Paus, Luebeck, Germany/Manchester, UK, vice president and responsible for experimental research, Mrs. Michelle Barlow, San Diego, CA, USA (former president, ex officio), treasurer and responsible for the

Foundation, Prof. Richard Gallo, San Diego, CA, USA, Dr. Ichiro Kurokawa, Nishinomiya, Japan, Dr. George Varigos, Melbourne, Australia, Dr. Jan Lapins, Stockholm, Sweden, Dr. Paul Hazen, Westlake, OH, USA, responsible for patients' communication and for the HSF Inc. website, Thomas Winkler, Germany, patients' representative, president Deutsche Interessengemeinschaft Akne inversa e.V., and Dr. Hessel H. van der See, Rotterdam, The Netherlands.

Despite the excellent and close cooperation among the involved scientists, the European Board members have recognized that bureaucratic issues in the USA made it more and more difficult for non-US citizens to run efficiently a US association. Therefore, Prof. Zouboulis resigned as HSF, Inc. president and member of the board on 27.02.2013 followed by Prof. Paus, leaving the leadership of the HSF, Inc. to US colleagues with Dr. Paul Hazen as new HSF, Inc. president from 02.03.2013. During its first meeting on 24.03.2014 the new HSF, Inc. board has granted Mrs. Michelle Barlow, Prof. Christos C. Zouboulis and Prof. Ralf Paus the honorary Founders HSF, Inc. membership.

#### INAUGURATION OF EHSF E.V.

The European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) has been inaugurated on 29.09.2012 in Prague, Czech Republic as independent, sister society of HSF, Inc. The EHSF e.V. has been registered and recognized as a non-profit, public benefit

organization (gemeinnuetziger e.V.) according to the German law. General assemblies, take place annually during the annual International Conference of the Society.

#### FOUNDING MEMBERS

- Dr. Jurr Boer, Deventer/The Netherlands
- Prof. Dr. Veronique del Marmol, Brussels/Belgium
- Dr. Nemesha Desai, London/United Kingdom
- Dr. Deirdre Nathalie Dufour, Kalundborg/Denmark
- Dr. Lennart Erntestam, Stockholm/Sweden
- Prof. Dr. Gregor B.E. Jemec, Roskilde/Denmark
- Dr. Łukasz Matusiak, Wrocław/Poland
- Prof. Dr. Thrasivoulos Tzellos, Harstad, Troms/Norway
- Thomas Winkler, Lüdinghausen/Germany
- Dr. Hessel H. van der Zee, Rotterdam/The Netherlands
- Prof. Dr. Christos C. Zouboulis, Dessau-Rosslau/Germany

## CONGRESSES

The 2<sup>nd</sup> International Hidradenitis Suppurativa Research Symposium took place on 05.03.2009 in San Francisco, IL, USA.

The 3<sup>rd</sup> International Hidradenitis Suppurativa Research Symposium (first of the EHSF e.V.) took place on 27.-28.02.2014 in Brussels, Belgium.

The 4<sup>th</sup> International Hidradenitis Suppurativa Research Symposium took place on 19.-20.02.2015 in Brussels, Belgium.

The 5<sup>th</sup> International Hidradenitis Suppurativa Conference, which was for the first time also open for non-members of the Society, took place on 10.-12.02.2016 in Berlin, Germany with 192 participants and 76 scientific contributions.

The 6<sup>th</sup> International Hidradenitis Suppurativa Conference took place on 8.-10.02.2017 in Copenhagen, Denmark with 202 participants and 77 scientific contributions.

The 7<sup>th</sup> International Hidradenitis Suppurativa Conference took place on 10.-12.02.2018 in Rotterdam, The Netherlands with more than 250 participants and 82 scientific contributions.

The 8<sup>th</sup> International Hidradenitis Suppurativa Conference took place on 10.-12.02.2019 in Wrocław, Poland with 406 participants and 119 scientific contributions.

The 9<sup>th</sup> International Hidradenitis Suppurativa Conference took place on 5.-7.02.2020 in Athens, Greece. 422 participants from 48 countries with 137 scientific contributions participated at the conference.

The 10<sup>th</sup> International Hidradenitis Suppurativa Conference took place – due to the COVID-19 pandemic – at a digital mode – 10.-12.02.2021. 138 scientific contributions were presented and 688 participants from 52 countries took part.

The 11<sup>th</sup> International Hidradenitis Suppurativa Conference took place – due to the COVID-19 pandemic – at a digital mode – 09.-11.02.2022. 138 scientific contributions were presented and 598 participants from 48 countries took part. with 12% of the participants were young scientists under the age of 30 years, a fact that guarantees a wide future of dermatology in the field of hidradenitis suppurativa.

The 12<sup>th</sup> International Hidradenitis Suppurativa Conference takes place hybrid from February 8-10, 2023 in Firenze.

## OUR GOALS

- The European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) pursues exclusively and directly charitable purposes within the meaning of the “tax-privileged purposes” of the tax code. Goal of the association is the promotion of science and research in field of the disease hidradenitis suppurativa/acne inversa.
- The goal of the association is raising funds for the promotion of research projects in the field of the disease hidradenitis suppurativa/acne inversa also to be achieved by support from other tax-exempt entities, public corporations or foreign entities whose activity is in line with the German Charity Law.

- Goal of the association is also the training of physicians, patients and laypersons.
- These goals are to be achieved
  - through raising funds for the support of scientific meetings for education of physicians, patients and laypersons also from other tax-exempt bodies, public corporations or foreign corporations whose business is through raising funds for the support of scientific meetings for continuing education of physicians, patients and laypersons in accordance with the German Charity Law,
  - through lectures of educational character and
  - through public relations. Goal of the association is also raising funds for the promotion of public health care in the field of the disease hidradenitis suppurativa/acne inversa also from other tax-exempt entities, public corporations or foreign corporations whose activities are in line with the German non-profit law.



# February 07-09, 2024

# 13TH CONFERENCE OF THE EUROPEAN HIDRADENITIS SUPPURATIVA FOUNDATION



## SAVE THE DATE

# EHSF ORGANIZING COMMITTEE



FRANCESCA PRIGNANO

(Firenze, Italy)



GREGOR B.E. JEMEC

(Roskilde, Denmark)



VERONIQUE DEL MARMOL

(Brussels, Belgium)



VINCENZO BETTOLI

(Bologne, Italy)



ANGELO V. MARZANO

(Milan, Italy)



ERROL P. PRENS

(Rotterdam, The Netherlands)




The Department of Dermatology, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium; the Department of Dermatology, Zealand University Hospital, University of Copenhagen, Roskilde, Denmark; the Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany; and the Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands are health care providers of the European Reference Network of Rare and Complex Skin Diseases (ERN Skin)



THRASYVOULOS TZELLOS

(Bodø, Norway)



CHRISTOS C. ZOUBOULIS

(Dessau, Germany)

## SCIENTIFIC COMMITTEE

Afsaneh Alavi

Erkan Alpsoy

Matthias Augustin

Edileia Bagatin

Falk Bechara

Pierre-André Becherel

Farida Benhadou

Vincenzo Bettoli

Yousef Binamer

Jurr Boer

Raffaele D. Caposiena Caro

Nisha S. Chandran

Arnon D. Cohen

Veronique Del Marmol

Maïa Delage-Toriel

Antonella Di Cesare

Alireza Firooz

John W. Frew

Ruta Ganceviciene

Simone Garcovich

Evangelos J. Giamarellos-Bourboulis

Katalin Glasenhardt

Matthias Goebeler

Noah I. Goldfarb

Philippe Guillem

Wayne Gulliver

Ariela Hafner

Iltefat Hamzavi

Yuval Hilerowicz

Barbara Hórvath

Evgenia Hristakieva

Robert E. Hunger

John R. Ingram

Dimitrios Ioannidis

Gregor B.E. Jemec

Olivier Join-Lambert

Qiang Ju

Alexander Katoulis

Lajos Kemény

Alexa B. Kimball

Brian Kirby

Joslyn S. Kirby

Nathalie Kirsten

Ishiro Kurokawa

Hjalmar Kurzen

Athanasios Kyrgidis

Michelle Lowes

Antonio Martorell

Angelo V. Marzano

Łukasz Matusiak

Dillon Mintoff

Alejandro Molina-Leyva

Haley Naik

Aude Nassif

Georgios Nikolakis

Hazel H. Oon

José C. Pascual Ramirez

Andreas Pinter

Maurizio Podda

Errol P. Prens

Dagmar Presser  
 Francesca Prignano  
 Luis Puig  
 Tadas Raudonis  
 Ziad Reguai  
 Jorge Romani  
 Marco Romanelli  
 Elia Rosi  
 Ditte M. Saunte  
 Christopher J. Sayed  
 Rodney Sinclair  
 Dae H. Suh  
 Andrea Szegedi  
 Jacek C. Szepietowski  
 Sylke Schneider-Burrus  
 Terui Tadashi  
 Linnea Thorlacius  
 Ann-Marie Tobin  
 Frangkiski Tsatsou  
 Thrasyvoulos Tzellos  
 Skaidra Valiukeviciene  
 Hessel H. van der Zee  
 Kelsey R. Van Straalen  
 Eva Vilarrasa  
 Esther von Stebut  
 Eva Vilarrasa  
 Seçil Vural  
 Baoxi Wang  
 Pierre Wolkenstein  
 Ximena Wortsman  
 Christos C. Zouboulis

## LOCAL ORGANIZING COMMITTEE

Francesca Prignano  
 Nicola Pimpinelli  
 Elia Rosi  
 Antonella Di Cesare

## OVERALL LEARNING OBJECTIVES

To present innovative basic and clinical research on hidradenitis suppurativa

To discuss and exchange opinions on new hidradenitis suppurativa treatment developments in an international setting

To address hidradenitis suppurativa unmet needs and future collaborative projects

## PRIZES

Submitted contribution prizes raised by the EHSF e.V. (1<sup>st</sup> prize 1000 €, 2<sup>nd</sup> prize 700 €, 3<sup>rd</sup> prize 400 €, 4<sup>th</sup> prize 200 €, 5<sup>th</sup> prize 100 €)

Young investigators prizes raised by the EHSF e.V. (3 prizes of 200 € for active participants under 30 year-old - lectures/poster presenters - who have to apply for the prize with CV, including date of birth and abstract submission)

## AWARDS COMMITTEE

Valentina Dini  
 Dante Caposiena  
 Giovanni Damiani  
 Simone Garcovich  
 Georgios Nikolakis

# WEDNESDAY PROGRAM OVERVIEW

Wednesday, February 08, 2023 10.00-19.00 (CET)		
10.00-13.00 (CET) Patient Association Representatives Chat Room	14.00-16.00 (CET) HS Nursing School	16.00-16.30 (CET) Welcome Addresses
16.30-17.00 (CET) Present recognitions from the EHSF	17.00-18.00 (CET) Invited Lecture – Plenary Session	18.00-20.00 (CET) Welcome Cocktail
12 <sup>th</sup> EHSF Conference Abstract Book Poster Viewing		

EHSF 2023 is a hybrid event. Join us on-site in Florence, Italy, or digitally at <https://conference.ehsf2023.com/>

08:00–11:00	<b>Scientific Symposium – Working Group for HS molecular mechanisms</b> (with invitation)
10:00–13:00	<b>Patient Association Representatives Chat Room</b>
14:00–16:00	<b>HS Nursing School</b> Let's talk about sex <i>Joanne L. Reeves</i>
16:00–16:30	<b>Welcome Addresses</b> <i>Paolo Bonanni</i> <i>Christos C. Zouboulis</i> <i>Nicola Pimpinelli</i> <i>Francesca Prignano</i> <i>Alessandra Petrucci</i>
16:30–17:00	<b>Present recognitions from the EHSF</b> Introduction <i>Gregor B.E. Jemec</i> Enthronization to the EHSF honorary members <i>Jurr Boer</i>
17:00–18:00	<b>Plenary Session: invited lectures</b> Chair: <i>Christos C. Zouboulis</i>
17:00 INV-0101	The place of surgery in HS <i>Philippe Guillem</i>
17:30 INV-0102	Oxidative stress and ROS: how they influence the inflammation in HS <i>Francesca Prignano</i>
18:00–20:00	<b>Welcome cocktail</b>

 All day

12<sup>th</sup> EHSF  
Conference  
Abstract Book

 All day

Poster  
Viewing  
on site and  
on the  
platform



# THURSDAY PROGRAM OVERVIEW

Thursday, February 09, 2023 08.00–18.30 (CET)		
08.00–09.00 (CET) General Assembly EHSF	09.00–10.00 (CET) Scientific Lectures 01 – Pathogenesis: new concerns from basic science and strength of acquired knowledge	10.15–11.45 (CET) Scientific Lectures 2 – Epidemiology, Registries, Genetics (clinical phenotypes, syndromes)
11.45–13.15 (CET) Scientific Symposium – GHSA Working Group	11.45–13.00 (CET) Lunch Break	13.00–14.30 (CET) Poster presentations I
14.30–15.30 (CET) Scientific Lectures 3 – Comorbidities	15.30–16.30 (CET) Scientific Lectures 3 – Diagnostic tools, Imaging: their increasing impact on HS diagnosis, classification, and treatment	

12<sup>th</sup> EHSF Conference Abstract Book  
Poster Viewing

EHSF 2023 is a hybrid event. Join us on-site in Florence, Italy, or digitally at <https://conference.ehsf2023.com/>

08.00–9.00	<b>General Assembly EHSF</b> (Members only)	All day 12 <sup>th</sup> EHSF Conference Abstract Book
09.00–10.00	<b>Pathogenesis: new concerns from basic science and strength of acquired knowledge</b> <i>Chairs:</i> <i>Francesca Prignano</i> <i>Errol P.rens</i>	All day Poster Viewing on site and on the platform
9:00 S-0101	IL-22 and its pathogenetic role in HS: a possible therapeutical target? <i>Kerstin Volk</i>	
9:10 S-0102	The microbiological difference between Hidradenitis Suppurativa tunnels and Crohn's disease perianal fistulas <i>Hans C. Ring</i>	
9:20 S-0103	Inflammatory and Fibrosis Related Gene Expression Patterns in Hidradenitis Suppurativa Lesions <i>Saba Khoshbakht</i>	
9:30 S-0104	Hippo pathway drives excessive fibrosis in Hidradenitis Suppurativa <i>Kelsey R. van Straalen</i>	
9:40 S-0105	Targeting the NLRP3 inflammasome reduces inflammation in hidradenitis suppurativa skin <i>Barry Moran</i>	
9:50 S-0106	New pharmaceutical technology from Germany: The HS 3D-SeboSkin model <i>Christos C. Zouboulis</i>	
10:00	Discussion	

10.15–11.45	<b>Epidemiology, Registries, Genetics (clinical phenotypes, syndromes)</b> <i>Chairs:</i> Veronique del Marmol Christos C. Zouboulis	 All day 12 <sup>th</sup> EHSF Conference Abstract Book
10.15 S-0201	The role of autoinflammation in syndromic HS Angelo V. Marzano	 All day Poster Viewing on site and on the platform
10.25 S-0202	How HS phenotypes correlate with acne Vincenzo Bettoli	
10.35 S-0203	Frequency and predictors of inflammatory bowel disease in patients with Hidradenitis Suppurativa – Results from the German HS Registry (HS-Best) Natalia Kirsten	
10.45 S-0204	Belgian patients of the European Registry for Hidradenitis Suppurativa (ERHS): data, scores and phenotypes since 2015 Anne-Sophie Sarkis	
10.55 S-0205	Hidradenitis phenotypes based on elementary lesions: description of a mixed phenotype with slowly progressive behavior Antonio Martorell	
11.05 S-0206	IPSCs derived skin organoids to understand the role of PSENEN genetic mutations in hidradenitis suppurativa Cécile N. Meddour	
11.15 S-0207	Genetic analysis of 100 Hidradenitis Suppurativa patients by whole exome sequencing Sophie Hue	
11.25	Discussion	
11.45–13.15	<b>GhISA Working Group</b> <i>Chairs:</i> Gregor E.B. Jemec	
11.45–13.00	<b>Lunch Break</b>	
13.00–14.30	<b>Poster presentations I</b> <i>Chairs and Awards Committee:</i> Valentina Dini Dante Caposiena Giovani Damiani Simone Garcovich Georgios Nikolakis	

14.30–15.30	<b>Comorbidities</b> <i>Chairs:</i> Anna Maria Offidani Ditte M.L. Saunte Hessel H. van der Zee	 All day 12 <sup>th</sup> EHSF Conference Abstract Book
14.30 S-0301	HS and psoriasis: data from registers and real-life evidence L. Naldi	 All day Poster Viewing on site and on the platform
14.40 S-0302	Occlusive follicular diseases and HS Ditte M.L. Saunte	
14.50 S-0303	Hidradenitis suppurativa and female infertility: A cross sectional pilot study Cecilia E. Medianfar	
15.00 S-0304	HS and IBD not only a comorbidity Hessel H. van der Zee	
15.10 S-0305	HS and atopic dermatitis Andrea Chiricozzi	
15.20	Discussion	
15.30–16.30	<b>Diagnostic tools, Imaging: their increasing impact on HS diagnosis, classification, and treatment</b> <i>Chairs:</i> Marco Romanelli Jacek Szepletowski Ximena Wortsman	
15.30 S-0401	Role of ultrahigh frequency ultrasound and EchoAngio software in HS Ximena Wortsman	
15.45 S-0402	Medical infrared thermography as HS diagnostic tool Skaidra Valiukevičienė	
15.55 S-0403	Discordances between clinic and ultrasound: who is the liar? Antonella Di Cesare	
16.05 S-0404	AI-aided automatic severity scoring system for Hidradenitis Suppurativa Tien Zung Nguyen	
16.15 S-0405	In vivo-ex vivo correlation of Hidradenitis Suppurativa anatomical lesions using Ultra-High Frequency Ultrasound and histopathological evaluation Giammarco Granieri	
16.25	Discussion	

# FRIDAY PROGRAM OVERVIEW

**Friday, February 10, 2023**  
08.00–18.00 (CET)


<p>08.00–09.00 (CET)</p> <p>Scientific Lectures 05 – Outcome measures, quality of life and unmet needs</p>	<p>09.00–10.00 (CET)</p> <p>Scientific Lectures 06 – Medical treatment: place in therapy of systemic “historical” drugs and new advancements from clinical trials – Part 1</p>	<p>10.00–11.00 (CET)</p> <p>Coffee Break and Poster Presentations II</p>
<p>11.00–12.00 (CET)</p> <p>Scientific Lectures 07 – Difficult cases/ resistant to treatment</p>	<p>11.55–12.50 (CET)</p> <p>Lunch Break</p>	<p>12.50–13.20 (CET)</p> <p>Scientific Lectures 08 – HS around the world: brief reports according to the many experiences worldwide (digital)</p>
<p>13.20–14.20 (CET)</p> <p>Scientific Lectures 09 – Medical treatment: place in therapy of systemic “historical” drugs and new advancements from clinical trials – Part 2</p>	<p>14.30–16.00 (CET)</p> <p>Coffee Break and Poster Presentations III</p>	<p>16.00–17.00 (CET)</p> <p>Scientific Lectures 10 – Surgical treatment: what is to consider a specific procedure for HS?</p>
<p>17.00–18.00 (CET)</p> <p>Scientific Lectures 11 – Conference awardee lectures and the young investigator awards: Hot HS results from the research bank</p>	<p>18.00 (CET)</p> <p>Closing remarks</p>	



12<sup>th</sup> EHSF Conference Abstract Book  
Poster Viewing

EHSF 2023 is a hybrid event. Join us on-site in Florence, Italy, or digitally at <https://conference.ehsf2023.com/>

08.00–9.00	<p><b>Outcome measures, quality of life and unmet needs</b></p> <p><i>Chairs:</i> Łukasz Matusiak Nicola Pimpinelli Thrasivoulos Tzellos</p>
8:00 S-0501	IHS4-55 Thrasivoulos Tzellos
8:10 S-0502	Hidradenitis Suppurativa Activity and Severity Index Revised (HASI-R): Past, present and future Noah I. Goldfarb
8:20 S-0503	Quality of life impairment in HS patients and reported outcomes: Pain Index App Łukasz Matusiak
8:30 S-0504	A global survey evaluating patients' unmet needs in hidradenitis suppurativa: Rationale, design and methodology Joslyn S. Kirby
8:40 S-0505	Considerations from the pharmaceutical industry Marcello Cattani
8:50	Discussion
09.00–10.00	<p><b>Medical treatment: place in therapy of systemic “historical” drugs and new advancements from clinical trials – Part 1</b></p> <p><i>Chairs:</i> Gregor B.E. Jemec John R. Ingram Christos C. Zouboulis</p>
9:00 S-0601	Anti-TNF-α treatment: from the success of PIONEER I and II studies to the results with anti-IL-17 monoclonal antibodies Christos C. Zouboulis
9:10 S-0602	The lesson from guidelines in antibiotic treatment in HS Kelsey R. van Straalen
9:20 S-0603	Photodynamic therapy with RLP068/CI as a new advancement in local treatment of HS Elia Rosi
9:30 S-0604	Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response – Data from the German HS Registry HSBest Frenz Ohm



 All day  
12<sup>th</sup> EHSF  
Conference  
Abstract Book

 All day  
Poster  
Viewing  
on site and  
on the  
platform

9:40 S-0605	Drug Survival of Metformin in Patients with Hidradenitis Suppurativa <i>José C. Pascual Ramirez</i>	 All day 12 <sup>th</sup> EHSF Conference Abstract Book
9:50	Discussion	
10.00–11.00	<b>Coffee Break and Poster Presentations II</b>	 All day Poster Viewing on site and on the platform
11.00–12.00	<b>Difficult cases/resistant to treatment</b> <i>Chairs:</i> <i>Angelo V. Marzano</i> <i>Concetta Potenza</i> <i>Errol P. Prens</i>	
11:00 S-0701	Doc, my anti-TNF is not working anymore, what to do next? <i>Errol P. Prens</i>	
11:10 S-0702	New surgical aproach in hidradenitis suppurativa surgical treatment - Co-Graft of Acellular Dermal Matrix and Split Thickness Skin Graft—A New Reconstructive Surgical Method <i>Marcin Gierak</i>	
11:15 S-0703	Hidradenitis suppurativa in transgender patients: a case series <i>Anne-Claire Fougerousse</i>	
11:20 S-0704	Pyogenic granuloma and hidradenitis suppurativa <i>Maria Musumeci</i>	
11:25 S-0705	A case of Hidradenitis Suppurativa, Conglobate Acne and Dissecting Cellulitis of the Scalp successfully treated with Secukinumab <i>Natale Schettini</i>	
11:30 S-0706	Paradoxical reactions during treatment with biological agents: reports of 3 cases <i>Aikaterini I. Liakou</i>	
11:35 S-0707	Advanced wound management approaches in hidradenitis suppurativa postsurgical lesions: the use of an oxygen-enriched oil-based medical device with prolonged release of reactive oxygen species <i>Alessandra Michelucci</i>	

11:40 S-0708	Ultrasonography-guided intralesional diode laser for the treatment of Hurley II hidradenitis suppurativa : Results from a pilot study with 46 procedures <i>Philippe Guillem</i>	 All day 12 <sup>th</sup> EHSF Conference Abstract Book
11:45	Discussion	
11.55–12.50	<b>Lunch Break</b>	 All day Poster Viewing on site and on the platform
12.50–13.20	<b>HS around the world: brief reports according to the many experiences worldwide (digital)</b> <i>Chairs:</i> <i>Antonella Di Cesare</i> <i>Elia Rosi</i>	
12:50	The GHiSA project <i>Gregor B.E. Jemec</i>	
12:55 S-0801	HS in the 25 <sup>th</sup> World Congress of Dermatology <i>Nishan S. Chandran</i>	
13:02 S-0802	HS in the Australasian area <i>John W. Frew</i>	
13:09 S-0803	HS developments in the USA <i>Joslyn S. Kirby</i>	
13.20–14.20	<b>Medical treatment: place in therapy of systemic “historical” drugs and new advancements from clinical trials - Part 2</b> <i>Chairs:</i> <i>Luca Bianchi</i> <i>Veronique del Marmol</i>	
13:20 S-0901	Secukinumab in moderate to severe hidradenitis suppurativa: Week 16 results of Hurley stage II and III from the SUNSHINE and SUNRISE Phase 3 randomised trials <i>Ziad Reguiai</i>	
13:30 S-0902	Efficacy of secukinumab in patients with hidradenitis suppurativa based on the International Hidradenitis Suppurativa Severity Scoring System (IHSS4): A post hoc analysis of the SUNSHINE and SUNRISE trials <i>Christos C. Zouboulis</i>	

13:40 S-0903	Assessment of the Performance of the IHS4-55 Using Data from a Phase 2 Study of Bimekizumab in Patients with Hidradenitis Suppurativa <i>Thrasyvoulos Tzello</i>	 All day 12 <sup>th</sup> EHSF Conference Abstract Book
13:50 S-0904	Adalimumab in conjunction with surgery compared with adalimumab monotherapy for Hidradenitis Suppurativa; a randomized controlled trial in a real-world setting <i>Pim Aarts</i>	 All day
14:00 S-0905	Impact of secukinumab on the need for rescue surgical intervention in patients with moderate to severe hidradenitis suppurativa: Post-hoc analysis of Week 16 data from SUNSHINE and SUNRISE trials <i>Hessel H. Van der Zee</i>	Poster Viewing on site and on the platform
14:10 S-0906	Janus Kinase 1 Inhibition With Povoricitinib (INCB054707) in Hidradenitis Suppurativa: Efficacy and Safety During the Open-Label Extension Period of a Phase 2 Study <i>Joslyn S. Kirby</i>	
14:20	Discussion	
<b>14.30–16.00 Coffee Break and Poster Presentations III</b>		
16.00–17.00	<b>Surgical treatment: what is to consider a specific procedure for HS?</b> <i>Chairs:</i> <i>Iacopo Giani</i> <i>Philippe Guillem</i> <i>Maurizio Podda</i>	
16:00 S-1001	Which surgery for which patient <i>Maurizio Podda</i>	
16:10 S-1002	Committed surgical treatment and post-surgical management of HS <i>Cristina Magnoni</i>	
16:20 S-1003	Combination of medical and surgical treatment: results and outcomes <i>Falk G. Bechara</i>	
16:30 S-1004	The use of seton drainage for hidradenitis suppurativa tunnels <i>Sara K. Saunte</i>	

16:35 S-1005	Management of hidradenitis suppurativa tunnels using drainage setons: retrospective, multicentric study <i>Javier Fernández-Vela</i>	 All day 12 <sup>th</sup> EHSF Conference Abstract Book
16:40 S-1006	Wound Care for Patients with Hidradenitis Suppurativa - Pearls and Pitfalls from a Specialist Clinic <i>Hannah E. Wainman</i>	
16:50	Discussion	 All day
17.00–18.00	<b>Conference awardee lectures and the young investigator awards: Hot HS results from the research bank</b> <i>Chairs:</i> <i>Christos C. Zouboulis</i> <i>Gregor B.E. Jemec</i> <i>Francesca Prignano</i>	Poster Viewing on site and on the platform
18.00	<b>Closing remarks</b>	

# POSTERS

## 1 | Clinics and Diagnostics

- P-003** When sebo-cystomatosis mimicks HS  
*Giulia Nunziati*
- P-009** Characteristics of patients with pediatric onset of hidradenitis suppurativa  
*Anne-Claire Fougereousse*
- P-015** The natural history study of hidradenitis suppurativa: A large-scale multicenter study in Turkey  
*Erkan Alpsoy*
- P-016** Screening of hidradenitis suppurativa in patients with axial spondyloarthritis  
*Rosa Fornons-Servent*
- P-022** Autosomal dominant hyperimmunoglobulin E syndrome : differential diagnosis or part of a new syndromic hidradenitis suppurativa ?  
*Philippe Guillem*
- P-039** Hidradenitis suppurativa and endocrinological comorbidities: a multidisciplinary, joint approach  
*Juan Garcias-Ladaria*
- P-040** Colonoscopy Findings in Hidradenitis Suppurativa  
*Nasro A. Isaq*
- P-043** Periodontal status in patients with hidradenitis suppurativa  
*Beata Jastrzqb*
- P-045** If PASH syndrome is not difficult enough!  
*Prisca Guerra*

- P-048** Psychiatric co-morbidity in patients with Hidradenitis Suppurativa: a cross sectional study examining demographic differences and burden of disease  
*Nikolaj Holgersen*
- P-049** Analysis of HS patient demographics and clinical data in Lithuania  
*Tadas Raudonis*
- P-050** Association of Dowling-Degos Disease in Hidradenitis Suppurativa patients  
*Patricia Garbayo-Salmons*
- P-051** Serum uric acid levels in hidradenitis suppurativa: a case-control study  
*María José Sánchez Pujol*
- P-054** Hidradenitis Suppurativa and Food Insecurity: A Stratified Analysis  
*Jain Shivani*
- P-055** Early impairment of endothelial and myocardial function in patients with hidradenitis suppurativa  
*Ourania Efthymiou*
- P-056** Paradoxical psoriasis in patients with hidradenitis suppurativa  
*Gemma Martin-Ezquerro*
- P-058** Overlapping Inflammatory Diseases in Hidradenitis Suppurativa Patients and Their Families  
*Elif E. Gülbezer*
- P-060** Hidradenitis suppurativa occurs in a specific familial context: results from a French prospective case-control study  
*Philippe Guillem*
- P-061** Inflammatory comorbidities in hidradenitis suppurativa: a retrospective monocentric study  
*Flaminia Antonelli*
- P-062** Prevalence of Abdominal Aortic Aneurysm in Patients with Hidradenitis Suppurativa in the VA Health Care System  
*Noah I. Goldfarb*
- P-064** Extrafacial demodicosis in a patient with Hidradenitis Suppurativa  
*Gavril R. Poterov*
- P-066** Positivity Rates of Contact Dermatitis Patch Testing in Hidradenitis Suppurativa Patients  
*Ning McKenzie*
- P-067** Hidradenitis suppurativa and pemphigus – a difficult to treat combination  
*Florentina S. Delli*
- P-068** Association of Hidradenitis Suppurativa (HS) with myeloid cells dysplasias [myelodysplastic (MDS) or myeloproliferative syndromes (MPS)]: 4 cases  
*Pierre-Andre Becherel*
- P-069** Hidradenitis suppurativa restricted to the pubic region in a woman with early menopause  
*Ivana Tusheva*
- P-070** Protocol for the use of ultrasound in Hidradenitis Suppurativa  
*Ariany T.A.S. Denofre*

- P-072** Antiphospholipid syndrome associated to severe Hidradenitis Suppurativa  
*Virginia R. Lopez Gamboa*
- P-073** Could dermoscopy be a helpful instrument to improve hidradenitis suppurativa diagnosis accuracy?  
*Anna Pirogova*
- P-074** Correlation of clinical and ultrasonography with color Doppler disease severity staging in Skin of Color patients of Hidradenitis Suppurativa  
*Sophia Rao*
- P-076** UHFUS with 70 MHz probe for the early anatomic detection of follicle obstruction in patients affected by hidradenitis suppurativa  
*Valentina Dini*
- P-078** Evaluation of Hidradenitis Suppurativa Through High-Field Magnetic Resonance and 3D Reconstruction - Experience of a Case  
*Luiza D'Almeida*
- P-087** Paediatric Hidradenitis suppurativa: follow up after 6 years. A descriptive study.  
*Verónica Mora-Fernández*
- P-091** "Lesion Journey" in Hidradenitis Suppurativa: clinical and ultrasonographic correlations.  
*Andrea Sechi*
- P-139** Clinical burden of hidradenitis suppurativa (HS) with draining tunnels  
*John Ingram*
- P-150** A non invasive assessment with a fluorescence device for the detection of colonized hidradenitis suppurativa lesions  
*Alessandra Michelucci*
- P-155** Hidradenitis Suppurativa and keloids with macro comedones: an aberrant presentation of Hidradenitis Suppurativa  
*Renata F. Magalhães*
- P-156** Investigation of Hidradenitis Suppurativa flares following COVID-19 vaccination: a cross sectional study.  
*Aikaterini I. Liakou*
- P-157** Clinical Practice Gaps in the Diagnosis and Management of Hidradenitis Suppurativa  
*Elaine D. Bell*
- P-158** Ectopic Hidradenitis Suppurativa: how difficult is it to diagnose and manage?  
*Patrícia Amoedo*
- P-160** Reasons for consultation in a tele mentoring project for Hidradenitis Suppurativa in Latin America  
*Virginia R. Lopez Gamboa*
- P-169** S-0102 The microbiological difference between Hidradenitis Suppurativa tunnels and Crohn's disease perianal fistulas  
*Hans C. Ring*

- P-175** S-0205 Hidradenitis phenotypes based on elementary lesions: description of a mixed phenotype with slowly progressive behavior  
*Antonio Martorell*
- P-178** S-0303 Hidradenitis suppurativa and female infertility: A cross sectional pilot study  
*Cecilia E. Medianfar*
- P-179** S-0403 Discordances between clinic and ultrasound: who is the liar?  
*Antonella Di Cesare*
- P-185** S-0703 Hidradenitis suppurativa in transgender patients: a case series  
*Anne-Claire Fougerousse*
- P-186** S-0704 Pyogenic granuloma and hidradenitis suppurativa  
*Maria Musumeci*

## 2 | Research

- P-019** Biomarkers for Hidradenitis Suppurativa risk: vitamin D receptor single nucleotide polymorphisms.  
*Cristina Membrive-Jiménez*
- P-020** Cytochrome P450 genes epigenetics should direct and instruct the therapeutical approach  
*Giovanni Damiani*
- P-021** Novel genetic variants and genes involved in the susceptibility to Hidradenitis suppurativa, the lesson from familiar cases  
*Paola Maura Tricarico*
- P-023** Epigenetic modulations are implicated in the disruption of the circadian rhythm in hidradenitis suppurativa  
*Uppala Radhakrishna*
- P-024** Unique B cell signature differentiates hidradenitis suppurativa from other inflammatory skin diseases psoriasis and atopic dermatitis.  
*Conor Smith*
- P-025** Characterization of an ex-vivo skin model of Hidradenitis suppurativa: pharmacological validation and evaluation of HS endotypes. HidraSME-I study (Hidra Skin Model Ex-vivo-I).  
*Núria Riera-Martí*
- P-026** Extensive Lymphocyte Clonal Expansion Occurs in the Tertiary Lymphoid Structures in Hidradenitis Suppurativa  
*Catherine P.-J. Lu*
- P-027** Pilot study of Gene expression profiling of skin in hidradenitis suppurativa Patients after Adalimumab Treatment  
*Elisabetta Botti*
- P-028** Immunological profile in patients with severe hidradenitis suppurativa: evolution after biological treatment  
*Cristina Ciudad Blanco*

- P-029** Metformin restores immune and metabolic dysregulation in hidradenitis suppurativa  
*Andreea Petrasca*
- P-030** Hippo pathway drives excessive fibrosis in Hidradenitis Suppurativa  
S-0104 *Kelsey R. van Straalen*
- P-031** Skin barrier alterations are not a characteristic feature of hidradenitis suppurativa  
*Krisztian Gaspar*
- P-032** Neutrophils and the IL-17 Axis Play a Key Pathological Role in Hidradenitis Suppurativa  
*Matthew Page*
- P-033** Role of gamma-secretase pathway in the pathogenesis of hidradenitis suppurativa and its correlation with Alzheimer's disease  
*Elisa Molinelli*
- P-034** An insight into the microbic world of HS  
*Gianmarco Silvi*
- P-035** Modulation of Hydrogen Sulfide in Hidradenitis Suppurativa  
*Evangelos J. Giamarellos-Bourboulis*
- P-036** Modulation of gut microbiome in hidradenitis suppurativa  
*Evangelos J. Giamarellos-Bourboulis*
- P-037** Neutrophil-derived B-cell activating factor supports B/plasma-cell persistence and function in skin lesions in Hidradenitis suppurativa/Acne inversa  
*Kerstin Wolk*
- P-084** Value of blood biomarkers of systemic inflammation in patients with hidradenitis suppurativa  
*Valdemar W. Nielsen*
- P-147** Hidradenitis suppurativa-like epidermis model  
*Isabel Haferland*
- P-151** Optimized human skin organ-culture conditions for pre-clinically exploring the impact of candidate therapeutics on hidradenitis suppurativa samples ex vivo  
*Marta Bertolini*
- P-152** Serum Amyloid A: a potential new marker of severity in hidradenitis suppurativa  
*Michela Iannone*
- P-153** Introduction of large language models for biomarker detection in hidradenitis suppurativa – chances and risks  
*Viktor A. Zouboulis*
- P-168** The Polygenic Architecture of Hidradenitis Suppurativa revealed by a first meta-analysis GWAS  
*Atlas Khan*
- P-170** Inflammatory and Fibrosis Related Gene Expression Patterns in Hidradenitis Suppurativa Lesions  
S-0103 *Saba Khoshbakht*

- P-171** Targeting the NLRP3 inflammasome reduces inflammation in hidradenitis suppurativa skin  
S-0105 *Barry Moran*
- P-172** New pharmaceutical technology from Germany: The HS 3D-SeboSkin model  
S-0106 *Christos C. Zouboulis*
- P-176** iPSCs derived skin organoids to understand the role of PSENEN genetic mutations in hidradenitis suppurativa  
S-0206 *Cécile N. Meddour*
- P-177** Genetic analysis of 100 Hidradenitis Suppurativa patients by whole exome sequencing  
S-0207 *Sophie Hue*
- P-180** AI-aided automatic severity scoring system for Hidradenitis Suppurativa  
S-0404 *Tien Zung Nguyen*
- P-181** In vivo-ex vivo correlation of Hidradenitis Suppurativa anatomical lesions using Ultra-High Frequency Ultrasound and histopathological evaluation  
S-0405 *Giammarco Granieri*

### 3 | Epidemiology and Registries

- P-002** Epidemiology and Comorbidity of Hidradenitis Suppurativa in Korea for 17 Years: A Korean Nationwide Population-based Cohort Study  
*Ji Hae Lee*
- P-004** Updated findings from the Global Hidradenitis Suppurativa COVID-19 Registry  
*Haley B. Naik*
- P-005** Prevalence of hidradenitis suppurativa in Poland  
*Klaudia P. Knecht-Gurwin*
- P-010** Characterizing Hidradenitis Suppurativa in Arabs: Analysis of two cohorts in Israel  
*Jen A. Barak Levitt*
- P-011** Prevalence and epidemiology of patients with Hidradenitis Suppurativa in the Faroe Islands  
*Amanda T. Brosbøl*
- P-012** Prevalence of Hidradenitis Suppurativa: results from the French team of the GHISA project  
*Philippe Guillem*
- P-014** Epidemiology and Clinical Features of Adult Patients with Hidradenitis Suppurativa in Germany: Baseline Characteristics from the German Hidradenitis Suppurativa registry HSBest  
*Frenz Ohm*
- P-017** Hidradenitis suppurativa reference center in Brazil:10-year analysis of Hospital de Clínicas da Unicamp, characterizing the profile of patients and treatments  
*Renata F. Magalhaes*
- P-041** Prevalence of Crohn's disease among pediatric patients with hidradenitis suppurativa  
*Nicole Mastacouris*
- P-042** Prevalence of atherosclerosis in hidradenitis suppurativa on coronary computed tomography angiography  
*Niamh Kearney*

- P-057** Comparative prevalence of pilonidal sinus disease in the general population and in patients with hidradenitis suppurativa: results from a French prospective case-control study  
*Philippe Guillem*
- P-059** Comparative prevalence of comorbidities in the general population and in patients with hidradenitis suppurativa: results from a French prospective case-control study  
*Philippe Guillem*
- P-063** Risk of hidradenitis suppurativa occurrence increases with familial history of smoking  
*Philippe Guillem*
- P-065** Prevalence of polycystic ovarian syndrome among children and adolescents with hidradenitis suppurativa  
*Nicole Mastacouris*
- P-173**  
S-0203 Frequency and predictors of inflammatory bowel disease in patients with Hidradenitis Suppurativa - Results from the German HS Registry (HS-Best)  
*Natalia Kirsten*
- P-174**  
S-0204 Belgian patients of the European Registry for Hidradenitis Suppurativa (ERHS): data, scores and phenotypes since 2015  
*Anne-Sophie Sarkis*

#### 4 | Outcome measures

- P-001** Understanding disease burden, unmet needs, treatment pathways and outcomes of patients with hidradenitis suppurativa in England: Rationale and design of a retrospective, non-interventional study  
*John Ingram*
- P-007** Hidradenitis suppurativa: study on factors influencing the course and severity of the disease  
*Luiza F. Vieira D'almeida*
- P-008** Influence of hormonal factors on women with hidradenitis suppurativa  
*Anne-Claire Fougerousse*
- P-013** The Study on Monitoring the Course of Hidradenitis Suppurativa patients  
*Vaiva Jariene*
- P-018** Can Hidradenitis suppurativa patients classify their own lesions by means of a Digital Lesion Identification Scheme?  
*Georgios Nikolakis*
- P-071** Power Doppler signal morphology as predictive factor of failure to adalimumab in hidradenitis suppurativa patients  
*Raffaele Dante Caposiena Caro*
- P-077** Comparison between clinical grade scales for hidradenitis suppurativa and the clinical-sonographic scoring system scale (SOS-HS).  
*Luiza D'Almeida*
- P-079** Psychometric assessment of the HiSQOL in adolescents with moderate-to-severe hidradenitis suppurativa  
*Joslyn S. Kirby*

- P-080** HiSQOL mini: A shortened version of the Hidradenitis Suppurativa Quality of Life (HiSQOL) instrument  
*Samar Hasan*
- P-082** A Systematic Literature Review of Health-Related Quality of Life and Other Patient Reported Outcomes Across Key Subgroups in Hidradenitis Suppurativa  
*Alexa B. Kimball*
- P-083** Validation of the HS-IGA: A Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials  
*Amit Garg*
- P-086** Comparison of the International Hidradenitis Suppurativa Severity Scoring System (IHS4) and Hurley staging in hidradenitis suppurativa disease severity assessment: A post hoc analysis of the SUNSHINE and SUNRISE phase 3 trials  
*Christos C. Zouboulis*
- P-088** A Core Outcome Set For Hidradenitis Suppurativa Trial Outcomes: An update from the HISTORIC initiative  
*Linnea Thorlacius*
- P-089** Severity of hidradenitis suppurativa is assessed differently by the patient and the practitioner  
*Philippe Guillem*
- P-092** Speed of progression: A new clinical parameter for therapeutic decision making in hidradenitis suppurativa  
*Eva Vilarrasa*
- P-093** Baseline knowledge of dermatology specialists/residents on hidradenitis suppurativa and immediate learning outcome after their participation at a European Academy of Dermatology and Venereology School  
*Christos C. Zouboulis*
- P-094** The excellent inter-rater reliability of IHS4 corroborates its aptitude as primary outcome measurement instrument for large clinical studies in hidradenitis suppurativa  
*Viktor A. Zouboulis*
- P-103** Potential predictors of cardiovascular risk improvement in patients with Hidradenitis Suppurativa treated with Adalimumab: A pivotal study of factors associated with carotid intima-media thickness reduction  
*Alejandro Molina-Leyva*
- P-104** Effectiveness, safety and potential predictors of response at week 16 in patients with severe hidradenitis suppurativa treated with secukinumab: a multicenter observational retrospective study  
*Alejandro Molina-Leyva*
- P-125** Inflammatory tunnel "railway sign": a new, independent, ultrasonographic predictor of adalimumab failure in patients with hidradenitis suppurativa  
*Piotr K. Krajewski*

- P-127** Does BMI influence healing after hidradenitis suppurativa surgery?  
*Anne Cecile Ezanno*
- P-128** Influence of smoking on healing after HS excisions.  
*Anne Cecile Ezanno*
- P-161** Intermittent Circadian Fasting may improve surgical outcomes in hidradenitis suppurativa patients: a ethnomedical, multicenter, retrospective observational study  
*Giovanni Damiani*

## 5 | Therapeutics

- P-006** Profile of patients treated with biotherapy for moderate to severe hidradenitis suppurativa in the OMCCI cohort  
*Anne-Claire Fougereousse*
- P-038** Paradoxical skin reaction after anti-TNF treatment for inflammatory bowel disease: should we include hidradenitis suppurativa?  
*Eleftheria Tampouratzi*
- P-047** SECUKINUMAB AS A THERAPEUTIC ALTERNATIVE FOR A KIDNEY-TRANSPLANT WOMAN WITH COEXISTING SYSTEMIC LUPUS AND RECALCITRANT HIDRADENITIS SUPPURATIVA  
*F. Javier Melgosa Ramos*
- P-052** New-onset inflammatory spondyloarthritis after a wide excision procedure in a patient with long-term HS and on adalimumab therapy  
*Antoanela Carija*
- P-075** Recurrence rates of Hidradenitis Suppurativa lesions explored with pre-surgical mapping with UHFUS  
*Flavia Manzo Margiotto*
- P-085** Successful Management of Hidradenitis Suppurativa complicated by Squamous Cell Carcinoma with Adalimumab – A case report  
*Amir Samadian*
- P-090** One year disease outcomes in patients with Hidradenitis Suppurativa treated with TNF-alpha inhibitors  
*Rositsa V. Lavcheva*
- P-095** Successful treatment of hidradenitis suppurativa with roflumilast: a case report with 10 months of follow-up  
*Maria Blomberg*
- P-096** Ertapenem for the treatment of hidradenitis suppurativa: a multicenter retrospective study. Description of candidate patients and administration route  
*Juan Manuel Segura Palacios*
- P-097** Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: real-life experience and therapeutic response to other biological drugs.  
*Lorenza Burzi*

- P-098** Guselkumab in the treatment of severe hidradenitis suppurativa, a promising role?  
*Lorenza Burzi*
- P-099** Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness?  
*Gabriele Roccuzzo*
- P-100** Drug survival of anti IL17 and IL23 agents after adalimumab failure in Hidradenitis Suppurativa: a single center experience.  
*Gabriele Roccuzzo*
- P-101** A Multi-failure case of HS with recurrent fever and flogistic state.  
*Ilaria Scandagli*
- P-102** Topical and Intralesional photodynamic therapy for hidradenitis suppurativa: A retrospective case series study of the University Hospital Son Espases.  
*Ines Gracia-Darder*
- P-105** Short Term Safety And Effectiveness Of Intralesional Galvanic Current In The Treatment Of Draining Tunnels Of Patients With Hidradenitis Suppurativa: Preliminary Results  
*Carlos Cuenca-Barrales*
- P-106** Retinoids use for hidradenitis suppurativa: a practice survey  
*Anne-Claire Fougereousse*
- P-107** Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a psoriasis patient  
*Fabrizio Martora*
- P-108** How Adalimumab impacts on antibiotic prescriptions in patients affected by hidradenitis suppurativa: a 1-year prospective study and retrospective analysis.  
*Fabrizio Martora*
- P-109** Tumor Necrosis Factor- $\alpha$  Inhibitor Prescription Patterns for Hidradenitis Suppurativa in the United States Veterans Affairs Healthcare System  
*Noah I. Goldfarb*
- P-110** Certilizumab on Treating Hidradenitis Suppurativa: A Promising Treatment Option  
*Asem Shadid*
- P-111** Adalimumab combined with apremilast, An effective treatment to rescue HS patients after secondary failure to adalimumab.  
*Blanca D. Ley*
- P-112** Ozenoxacin effectiveness in hidradenitis suppurativa  
*Pablo Fernandez-Crehuet*
- P-113** Long term efficacy of secukinumab in HS patients: a case series  
*Dalma Malvaso*
- P-114** Complications related to the use of adalimumab in specialized outpatient center in hidradenitis suppurativa – Original article  
*Mariana M. Rechuan*

- P-115** Efficacy of two different Ixekizumab protocols in the management of recalcitrant Hidradenitis Suppurativa  
*Flavia Manzo Margiotta*
- P-116** A new ultraportable negative pressure wound therapy in the management of hidradenitis suppurativa post surgical lesions: a case report  
*Giammarco Granieri*
- P-117** A patient with hidradenitis suppurativa and psoriasis treated with Brodalumab who developed pyoderma gangrenosum : a paradoxical reaction?  
*Giorgia Salvia*
- P-118** Nonsteroidal anti-inflammatory drugs and the risk of hidradenitis suppurativa  
*Philippe Guillem*
- P-119** Factors associated with patients self-reported response to treatments in hidradenitis suppurativa  
*Philippe Guillem*
- P-120** Long-term efficacy and safety of brodalumab in a patient with hidradenitis suppurativa and concomitant palmo-plantar psoriasis  
*Manfredo Bruni*
- P-121** Efficacy and safety of modified-release doxycycline 40 mg for the treatment of hidradenitis suppurativa  
*Gemma Camiña-Conforto*
- P-122** Systemic corticoids as a salvage therapy in severe multi-resistant Hidradenitis Suppurativa  
*Pierre-Andre Becherel*
- P-123** Photodynamic therapy with Zn(II) phthalocyanine (RLP068/CI) for hidradenitis suppurativa  
*Marina Venturini*
- P-124** Orisnilast for Mild to Severe Hidradenitis Suppurativa: Preliminary Data from OSIRIS, a Phase 2a, Open-Label, Single-Center, Single-Arm Clinical Trial  
*Camilla Goetzsche Frederiksen*
- P-126** Management of hidradenitis suppurativa tunnels using drainage setons: retrospective, multicentric study  
S-1005  
*Javier Fernández-Vela*
- P-129** Efficacy and safety of the combined medical and surgical approaches in patients affected by hidradenitis suppurativa  
*Dalma Malvaso*
- P-130** How does the patient's life change after surgical treatment ? Impact of Hidradenitis Suppurativa Surgical Treatment on Health-Related Life Quality  
*Marcin Gierek*
- P-131** A case of a therapy resistant Hidradenitis Suppurativa and underlying Crohn's Disease  
*Merve Akdeniz*

- P-142** Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Analysis of Pooled Data from the SUNSHINE and SUNRISE Phase 3 Randomized Trials  
*Afsaneh Alavi*
- P-143** The MIRA trial: A global, randomized, double-blind, placebo-controlled Phase 2 trial to evaluate the efficacy and safety of the IL-17A- and IL-17F-inhibiting Nanobody® sonelokimab in patients with active, moderate-to-severe hidradenitis suppurativa  
*Brian Kirby*
- P-144** Effect of secukinumab on draining tunnels in patients with moderate to severe hidradenitis suppurativa: Post hoc analysis of the SUNSHINE and SUNRISE Phase 3 randomised trials  
*Falk G. Bechara*
- P-145** Burden of Pain and Use of Pain Medications in Patients with HS: Real-World Data from UNITE  
*Lauren Orenstein*
- P-146** A centre-based, ambulatory care concept for Hidradenitis suppurativa improves disease activity, burden and patient satisfaction – Results from the randomized controlled trial EsmAiL  
*Michael Schultheis*
- P-148** Antibiotic resistances in hidradenitis suppurative patients treated with adalimumab  
*Terenzio Cosio*
- P-149** New insights on HS phenotypes and treatment response: A post hoc analysis of SUNSHINE and SUNRISE Phase 3 trials  
*Anna Passera*
- P-162** Piperacillin/tazobactam treatment as a crisis therapy in Hidradenitis suppurativa patients: a Series of 10 Patients  
*Aviv Barzilai*
- P-163** New surgical aproach in hidradenitis suppurativa surgical treatment - Co-Graft of Acellular Dermal Matrix and Split Thickness Skin Graft–A New Reconstructive Surgical Method  
S-0702  
*Marcin Gierek*
- P-167** Switching from intravenous to subcutaneous infliximab in patients with hidradenitis suppurativa  
*Mar Luque*
- P-182** Photodynamic therapy with RLP068/CI as a new advancement in local treatment of HS  
S-0603  
*Elia Rosi*
- P-183** Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response – Data from the German HS Registry HSBEST  
S-0604  
*Frenz Ohm*
- P-184** Drug Survival of Metformin in Patients with Hidradenitis Suppurativa  
S-0605  
*José C. Pascual Ramirez*
- P-187** A case of Hidradenitis Suppurativa, Conglobate Acne and Dissecting Cellulitis of the Scalp successfully treated with Secukinumab  
S-0705  
*Natale Schettini*

- P-188**  
S-0706 Paradoxical reactions during treatment with biological agents: reports of 3 cases  
*Aikaterini I. Liakou*
- P-189**  
S-0707 Advanced wound management approaches in hidradenitis suppurativa postsurgical lesions: the use of an oxygen-enriched oil-based medical device with prolonged release of reactive oxygen species  
*Alessandra Michelucci*
- P-190**  
S-0708 Ultrasonography-guided intralesional diode laser for the treatment of Hurley II hidradenitis suppurativa : Results from a pilot study with 46 procedures  
*Philippe Guillem*
- P-191**  
S-0901 Secukinumab in moderate to severe hidradenitis suppurativa: Week 16 results of Hurley stage II and III from the SUNSHINE and SUNRISE Phase 3 randomised trials  
*Ziad Reguiai*
- P-192**  
S-0902 Efficacy of secukinumab in patients with hidradenitis suppurativa based on the International Hidradenitis Suppurativa Severity Scoring System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials  
*Christos C. Zouboulis*
- P-193**  
S-0903 Assessment of the Performance of the IHS4-55 Using Data from a Phase 2 Study of Bimekizumab in Patients with Hidradenitis Suppurativa  
*Thrasyvoulos Tzellos*
- P-194**  
S-0904 Adalimumab in conjunction with surgery compared with adalimumab monotherapy for Hidradenitis Suppurativa; a randomized controlled trial in a real-world setting  
*Pim Aarts*
- P-195**  
S-0905 Impact of secukinumab on the need for rescue surgical intervention in patients with moderate to severe hidradenitis suppurativa: Post-hoc analysis of Week 16 data from SUNSHINE and SUNRISE trials  
*Hessel H. Van der Zee*
- P-165**  
S-0906 Janus Kinase 1 Inhibition With Povorcitinib (INCB054707) in Hidradenitis Suppurativa: Efficacy and Safety During the Open-Label Extension Period of a Phase 2 Study  
*Joslyn S. Kirby*
- P-196**  
S-1004 The use of seton drainage for hidradenitis suppurativa tunnels  
*Sara K. Saunte*
- P-197**  
S-1006 Wound Care for Patients with Hidradenitis Suppurativa - Pearls and Pitfalls from a Specialist Clinic  
*Hannah E. Wainman*

## 6 | Quality of life / Nurse and patient reports

- P-044** Hidradenitis suppurativa and psychopathology: the chicken or the egg?  
*Jorge Romani*
- P-046** A Cross-sectional Study of Fatigue, Depression and Anxiety in Patients with Hidradenitis Suppurativa Compared to the General Population of Denmark.  
*Camilla G. Frederiksen*

- P-081** Satisfaction with life among patients with hidradenitis suppurativa: a cross-sectional study.  
*Julia E. Rymaszewska*
- P-132** Nurse-led annual consultations for patients with Hidradenitis Suppurativa: Impressions and characteristics  
*Stine H. Pedersen*
- P-133** Assessment of depression in hidradenitis suppurativa: how to improve the management of the patients  
*Sara Anton Fernandez*
- P-134**  
S-0504 A global survey evaluating patients' unmet needs in hidradenitis suppurativa: Rationale, design and methodology  
*Joslyn S. Kirby*
- P-135** Quality-of-life endpoints in women of childbearing age with hidradenitis suppurativa: a tertiary-care-centre-based study  
*Aikaterini Tsentemidou*
- P-136** Impact of Hidradenitis Suppurativa on Major Life Changing Decisions  
*Carlos Cuenca-Barrales*
- P-137** Psychoeducational intervention in hidradenitis suppurativa through a patient engagement program  
*Francisco José Rodríguez-Cuadrado*
- P-138** Sleeping Disorders of patients suffering from Hidradenitis Suppurativa in relevance with Sleeping Quality INDEX PITTSBURG.GR PSQI - GOOD SLEEPERS AND BAD SLEEPERS  
*Tryfon Papadopoulos*
- P-140** Quality of life, anxious and depressive symptoms and mental disorders in a sample of Spanish hidradenitis suppurativa patients starting a biologic treatment.  
*Marta Loro-Pérez*
- P-141** Signs, Symptoms, Clinical Severity of Hidradenitis Suppurativa and its Impact on Quality of Life  
*Luiza F. D'Almeida*
- P-154** Determinants of appointment absenteeism at a tertiary Hidradenitis Suppurativa outpatient clinic  
*Britt Nilausen*
- P-159** Paramedics And Nurses Against Suppurative Hidradenitis (PANASH): an example of nurse involvement in clinical research  
*Philippe Guillem*
- P-166** wHoiS  
*Giuseppina Pintori*

[illegible][illegible]

# EHSF IMPRINT

**Scientific Organizer**

European Hidradenitis Suppurativa  
Foundation e.V.  
Auenweg 38, 06847 Dessau-Rosslau  
[www.ehsf.eu](http://www.ehsf.eu)

Prof. Dr. Christos C. Zouboulis  
President of the EHSF e.V.

**Professional Congress Organizer**

MCI Deutschland GmbH  
Markgrafenstrasse 56  
10117 Berlin  
T: +49 30 20459230  
F: +49 30 2045950

**Congress venue**

Firenze Fiera S.p.A.  
Congress & Exhibition Center  
Sede Legale e Operativa: Piazza Adua, 1  
50123 Firenze (Italy)

**Contact**

Project Management  
Viktoria Solotar  
T: +49 30 20459374  
[ehsf@wearemci.com](mailto:ehsf@wearemci.com)

Sponsoring/Exhibition  
Kristina Van Cleave  
T: +49 30 20459469  
[ehsf-sponsoring@wearemci.com](mailto:ehsf-sponsoring@wearemci.com)



[www.ehsf2023.com](http://www.ehsf2023.com)